Leukemia, Myelodysplastic Syndromes
Conditions
Keywords
myelodysplastic syndromes, acute myeloid leukemia
Brief summary
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients at risk of developing myelodysplastic syndrome may help doctors learn more about changes that occur in DNA and identify biomarkers related to disorders of the blood and bone marrow. PURPOSE: This research study is looking at biomarkers in patients at risk of developing myelodysplastic syndrome or other disorders and in healthy participants.
Detailed description
OBJECTIVES: Primary * To identify novel biomarkers of disease that would help in the initial diagnosis of myelodysplastic syndromes (MDS). Secondary * To understand the genesis of anemia in cancers. * To identify novel biomarkers of disease that predict progression of MDS to acute myeloid leukemia. OUTLINE: Blood and bone marrow samples are collected. Hemopoietic stem cells (HSC) and progenitor cells are isolated from samples for analysis. Some of these HSC and progenitor cells are used for functional assays. From the rest of the cells, DNA, RNA, and protein is extracted for molecular analyses, including gene mutation analysis, gene methylation assays, chromatin immunoprecipitation, microarray, and real-time polymerase chain reaction.
Interventions
GENETICDNA methylation analysis
GENETICRNA analysis
GENETICcytogenetic analysis
GENETICgene expression analysis
GENETICmutation analysis
GENETICpolymerase chain reaction
GENETICprotein expression analysis
OTHERlaboratory biomarker analysis
Sponsors
Oxford University Hospitals NHS Trust
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
DISEASE CHARACTERISTICS: * Must meet 1 of the following criteria: * Being investigated for a potential blood disorder due to abnormal blood count * Patients with a known blood disorder who are having a bone marrow sample taken as part of the assessment of that disorder * Patients undergoing hip replacement surgery at Nuffield Orthopaedic Centre, Oxford meeting the following criteria: * Not on treatment likely to impair bone marrow function * No history of having had treatment likely to have impaired bone marrow function * Normal blood count * Archived samples from patients with known blood disorder PATIENT CHARACTERISTICS: * See Disease Characteristics PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of novel biomarkers of disease | — |
Secondary
| Measure | Time frame |
|---|---|
| Identification of novel biomarkers of disease progression from myelodysplastic syndromes to acute myeloid leukemia | — |
| Comprehension of genesis of anemia in cancer | — |
Countries
United Kingdom
Outcome results
None listed